Spruce Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate UpdatesBusiness Wire • 11/13/23
Spruce Biosciences to Participate in the Jefferies London Healthcare ConferenceBusiness Wire • 11/02/23
Top 4 Health Care Stocks That May Rocket Higher This Month - Generation Bio (NASDAQ:GBIO), Evelo Biosciences (NASDAQ:EVLO)Benzinga • 10/20/23
Spruce Biosciences Completes Target Enrollment of CAHmelia-203 Study in Adult Classic Congenital Adrenal HyperplasiaBusiness Wire • 10/18/23
Spruce Biosciences to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceBusiness Wire • 08/28/23
Spruce Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate UpdatesBusiness Wire • 08/14/23
Spruce Biosciences Announces Acceptance of Abstract for Presentation at the Annual Meeting of the Endocrine Society (ENDO 2023)Business Wire • 06/12/23
Spruce Biosciences Honored at CARES Foundation 15th Annual Everyone CARES GalaBusiness Wire • 05/22/23
Spruce Biosciences Reports First Quarter 2023 Financial Results and Provides Corporate UpdatesBusiness Wire • 05/15/23
Spruce Biosciences to Present Findings on Retrospective Analysis of Completion Rates for CAH Studies at Pediatric Endocrine Society 2023 Annual MeetingBusiness Wire • 05/04/23
Spruce Biosciences, Inc. (SPRB) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 03/31/23
Spruce Biosciences Reports Full Year 2022 Financial Results and Provides Corporate UpdatesBusiness Wire • 03/16/23
Spruce Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare ConferenceBusiness Wire • 02/28/23
Spruce Biosciences to Participate in the SVB Securities Global Biopharma ConferenceBusiness Wire • 02/01/23
Spruce Biosciences, Inc. (SPRB) Now Trades Above Golden Cross: Time to Buy?Zacks Investment Research • 01/31/23
Spruce Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023Business Wire • 01/09/23
Spruce Biosciences and Kaken Pharmaceutical Announce Strategic Partnership and Exclusive Licensing Agreement to Develop and Commercialize Tildacerfont for CAH in JapanBusiness Wire • 01/05/23
Spruce Biosciences Reports Third Quarter 2022 Financial Results and Provides Corporate UpdatesBusiness Wire • 11/10/22